A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
about
A design for phase I trials in completely or partially ordered groups.Identifying a maximum tolerated contour in two-dimensional dose finding.Practical designs for Phase I combination studies in oncologyA comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administrationAdaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.Some statistical considerations in the clinical development of cancer immunotherapies.A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.Design considerations for early-phase clinical trials of immune-oncology agents
P2860
Q30252706-0119D782-1EA0-4256-BD06-F98A12B8EA74Q30277277-26E24003-547B-4494-A4AA-9D74FDAE98AAQ30278669-23075044-6039-4400-9571-230E3EC275E0Q30299951-2C2CB6B7-2A40-4D7F-AF11-26F218039174Q37505622-3BAA8DCB-2C01-47BB-8577-005FAB26A9EAQ38608632-C70A14C0-4D62-4D46-AE2C-C09B4284B1A0Q44494502-6E52B8B5-D802-450C-922C-3F1C8C79E68CQ48369935-BD3789A2-2B20-427C-8334-6D1C4799E3E7Q49233311-F6C5788B-3D40-440D-8F7A-9A60BA2596BBQ54957800-CD3EEB8C-44A4-43FD-A447-400326C75CA5Q56334001-959F76EF-8A8C-411F-8A2A-105C955DF06D
P2860
A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A product of independent beta ...... for dual-agent phase I trials.
@en
A product of independent beta ...... for dual-agent phase I trials.
@nl
type
label
A product of independent beta ...... for dual-agent phase I trials.
@en
A product of independent beta ...... for dual-agent phase I trials.
@nl
prefLabel
A product of independent beta ...... for dual-agent phase I trials.
@en
A product of independent beta ...... for dual-agent phase I trials.
@nl
P2860
P356
P1476
A product of independent beta ...... for dual-agent phase I trials
@en
P2093
Adrian P Mander
Michael J Sweeting
P2860
P304
P356
10.1002/SIM.6434
P407
P577
2015-01-29T00:00:00Z